北京时间9月1日21:38,格拉斯哥大学心血管与医学科学研究中心-心血管研究中心的John McMurray教授在ESC(欧洲心脏病学会年会)正式公布了DAPA-HF(达格列净预防心衰不良结局研究)的结果。 DAPA-HF:划时代的研究结果 DAPA-HF是首个在伴或不伴2型糖尿病的射血分数降低心衰患者中应用SGLT2抑制剂治疗的心衰结局研究。研究...
除了上面两项分析之外,当地时间11月16日,在2019AHA年会上还发布了另一项DAPA-HF最新分析结果,无2型糖尿病的HFrEF患者接受SGLT2抑制剂达格列净10mg qd治疗具有明显获益。(详见:DAPA-HF:达格列净改善心衰预后,伴或不伴糖尿病患者均获益|AHA...
Four large-scale trials in type 2 diabetes have shown that sodium-glucose cotransporter 2 (SGLT2) inhibitors prevent the occurrence of serious heart failure events. Additionally, the DAPA-HF trial demonstrated a benefit of da...
A 2020 review of the DAPA-HF trial noted that dapagliflozin was similarly effective and safe in patients who were taking sacubitril/valsartan compared to those who were not, suggesting that the use of both agents together could be of benefit in patients with HFrEF [2]. In the 2020 EMPEROR-...
[1]Farxiga approved in the US to reduce the risk of hospitalisation for heart failure in patients with type-2 diabetes. Retrieved Oct 21, 2019, from网页链接 [2]Farxiga met primary endpoint in landmark Phase III DAPA-HF trial for the treatment of patients with heart failure. Retrieved August...
In a randomized trial of patients with heart failure and reduced ejection fraction, the SGLT2 inhibitor dapagliflozin markedly reduced mortality and worsening heart failure (McMurray et al., 2019). Remarkably, these benefits seemed to be similar in people with and without diabetes. These data usher...
PHILADELPHIA — New analyses of the DAPA-HF trial suggest that the benefits of the SGLT2 inhibitor dapagliflozin extend beyond its effects as a type 2 diabetes therapy. On the heels of the main DAPA-HF results presented at the Euro...
The term gamechanger is overused but may be appropriate for the DAPA-HF trial on the SGLT2 inhibitor dapagliflozin in patients with heart failure and reduced ejection fraction. Medical conservative John Mandrola, MD, was impressed.
Dapagliflozin was similarly efficacious and safe in patients who were and who were not taking sacubitril/valsartan in the DAPA-HF trial, which suggested that the use of both agents together could further lower morbidity and mortality in patients with HFrEF. (Dapagliflozin And Prevention of Adverse...
Cardiovascular outcome trials with empagliflozin, canagliflozin and dapagliflozin have demonstrated reductions in major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke)1鈥 3 and hospitalisation for heart failure.4鈥 6 A dedicated renal outcomes trial with...